PHARMACEUTICAL PREPARATIONS FOR ADDICTION TREATMENT

用于成瘾治疗的药物制剂

• 批准号: 6344343
• 负责人: RAM B. MURTY
• 金额: $ 30万
• 依托单位: MURTY PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6344343
• 关键词: drug /agent; drug abuse chemotherapy; drug administration routes; drug design /synthesis /production; drug detection; drug metabolism; drug quality /standard; drug screening /evaluation; pharmacology; toxicology

The Contractor shall serve as a drug formulations resource in support of preclinical pharmacological/toxicological evaluations and clinical trials. In brief, the objectives of this contract are to determine the physical and chemical characteristics of a drug substance to develop the substance into clinically useful formulations. It involves identifying the chemical characteristics of the drug and its compatibility with various solvents, reagents and inactive ingredients, and its stability to environmental conditions (e.g., light, temperature, humidity). The formulation must be compatible with the route of administration intended, the drug's metabolism upon administration and its ability to achieve a clinically effective tissue/target concentration. Patient compliance issues, such as: each of use; frequency and route of administration; and diversion to illegal use must also be considered when formulating a new dosage or a new drug substance. The data and products generated by this contract will be utilized by the NIDA Medications Development Division (MDD) in developing and testing pharmaceutical preparations in the treatment of drug addictions.

承包商应作为药物制剂资源，以支持 临床前药理学/毒理学评价和临床试验。 简而言之，本合同的目的是确定 和化学特性，以开发该物质 临床上有用的制剂。它涉及到识别化学物质 药物的特性及其与各种溶剂的相容性， 试剂和非活性成分，及其对环境的稳定性 条件（例如，光、温度、湿度）。制剂必须是 与预期的给药途径相容， 其在施用后的代谢以及其实现临床上 有效组织/目标浓度。患者依从性问题，例如： 每种用途;给药频率和途径;以及转移至 当配制新剂量或新制剂时， 原料药。本合同产生的数据和产品将 由NIDA药物开发部（MDD）用于开发 和测试药物制剂在药物治疗中的作用 上瘾